Bremelanotide

The approved branded form of the compound sold as PT-141, indicated for hypoactive sexual desire disorder in premenopausal women.

Bremelanotide is classified as a melanocortin receptor agonist. Its current development status is: fda-approved (branded form). Multiple randomised controlled trials in humans support the primary claims made for this compound.

The Peptide Institute tracks Bremelanotide because it is actively sold through research-compound and telehealth channels. Our interest is narrow and specific: what is actually in the vial, whether the label is accurate, and whether the sellers of it can document what they claim. We take no position on whether anyone should use it.